Insulin glargine (IGla) is a synthetic human-recombinant insulin analog that is used routinely in people as a q24h basal insulin. The 300 U/mL (U300) formulation of IGla is associated with longer duration of action and less within-day variability, making it a better basal insulin compared with the 100 U/mL (U100) formulation. We hypothesized that in healthy cats, IGlaU300 has a flatter time-action profile and longer duration of action compared with IGlaU100. Seven healthy neutered male, purpose-bred cats were studied in a randomized, crossover design. Pharmacodynamics of IGlaU100 and IGlaU300 (0.8 U/kg, subcutaneous) were determined by the isoglycemic clamp method. The time-action profile of IGlaU300 was flatter compared with IGlaU100 as demonstrated by lower peak (5.6 ± 1.1 mg/kg/min vs 8.3 ± 1.9 mg/kg/min, respectively; P = 0.04) with no difference in total metabolic effect (ME; P = 0.7) or duration of action (16.8 h ± 4.7 h vs 13.4 h ± 2.6 h; P = 0.2). The greater fraction of ME in the 12- to 24-h period postinjection (35 ± 23% vs 7 ± 8% respectively; P = 0.048) and lower intraday GIR% variability (7.8 ± 3.7% vs 17.4 ± 8.2% respectively; P = 0.03) supports a flatter time-action profile of IGlaU300. There were no differences in onset and end of the action. In summary, although both formulations have a similar duration of action that is well below 24 h, the ME of IGlaU300 is more evenly distributed over a 24 h period in healthy cats, making it a better candidate for once-daily injection in diabetics compared with IGlaU100.

甘精胰岛素 (IGla) 是一种合成的人重组胰岛素类似物，作为 q24h 基础胰岛素在人群中常规使用。与 100 U/mL (U100) 制剂相比，300 U/mL (U300) 的 IGla 制剂具有更长的作用持续时间和更少的日内变异性，使其成为更好的基础胰岛素。我们假设在健康猫中，与 IGlaU100 相比，IGlaU300 具有更平坦的时间-作用曲线和更长的作用持续时间。在随机交叉设计中研究了七只健康的绝育雄性猫。IGlaU100 和 IGlaU300（0.8 U/kg，皮下）的药效学通过等糖钳夹法测定。IGlaU300 的时间-作用曲线与 IGlaU100 相比更平坦，如较低的峰值所示（分别为 5.6 ± 1.1 mg/kg/min 和 8.3 ± 1.9 mg/kg/min；P = 0.04），总代谢效应（ME；P = 0.7）或作用持续时间（16.8 h ± 4.7 h vs 13.4 h ± 2.6 h；P = 0.2）没有差异。注射后 12 至 24 小时内 ME 的比例更大（分别为 35 ± 23% 和 7 ± 8%；P = 0.048）和更低的日内 GIR% 变异性（分别为 7.8 ± 3.7% 和 17.4 ± 8.2%；P = 0.03) 支持 IGlaU300 更平坦的时间-动作曲线。动作的开始和结束没有差异。总之，虽然两种制剂的作用持续时间相似，远低于 24 小时，但 IGlaU300 的 ME 在健康猫中的 24 小时内分布更均匀，使其成为糖尿病患者每日一次注射的更好候选者。 IGlaU100。